SCHEDULE: Gyre Therapeutics Completes $300M Cullgen Acquisition

Gyre Therapeutics has finalized its all-stock merger with Cullgen Inc., resulting in significant ownership changes and the issuance of new convertible preferred stock.

Summary

• Completed the acquisition of Cullgen Inc. on May 4, 2026, in an all-stock transaction.
• The transaction valued Cullgen at approximately $300 million.
• Ying Luo and Ping Lan now beneficially own 10,211,387 shares, representing 8.6% of the company.
• Issued Series B Preferred Stock convertible into common stock at a 1:5 ratio, pending shareholder approval.
• Total shares outstanding increased to 119,080,374 following the merger and option inclusions.
• A stockholder meeting is scheduled for June 10, 2026, to vote on the conversion of Series B Preferred Stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive strategic milestone that expands the company's asset base, though the resulting dilution and the requirement for an upcoming shareholder vote add layers of complexity.

Positives

• Successful closing of a major $300 million strategic acquisition to expand the company portfolio.
• Implementation of tiered lock-up agreements for key insiders, preventing immediate mass sell-offs for up to 18 months.
• The all-stock nature of the deal preserves cash reserves for operational use.
• Reporting persons Ying Luo and Ping Lan maintain a significant 8.6% stake, aligning management interests with shareholders.

Negatives

• Significant dilution of existing shareholders due to the issuance of 14,450,527 new shares and potential preferred stock conversions.
• Complexity of the Series B Preferred Stock structure requires further regulatory and shareholder hurdles.
• The company is obligated to pay all fees and expenses related to the resale registration of the new shares.

Risks

• Shareholder approval for the Conversion Proposal is not guaranteed, which could complicate the capital structure.
• Potential for future selling pressure as lock-up periods expire at 6, 12, and 18 months.
• Integration risks associated with the $300 million acquisition of Cullgen and its transition to a wholly owned subsidiary.
• Conversion of Series B Preferred Stock is prohibited if it causes a holder to exceed a 19.99% ownership threshold.

Future Outlook

The company is focused on obtaining shareholder approval for the conversion of Series B Preferred Stock and integrating Cullgen's operations. A resale registration statement must be filed within 45 days of the merger closing to allow new shareholders to sell their positions subject to lock-up restrictions.

Management Comments

• Ying Luo received options to purchase 2,136,473 shares of Company Common Stock in exchange for Cullgen options.
• The merger was consummated as an all-stock transaction valuing Cullgen at approximately $300 million.

Industry Context

StockSavvy.ai notes that this merger reflects a continuing trend of consolidation in the biotech sector, where companies use all-stock deals to acquire platform technologies or pipeline assets without depleting cash reserves during volatile market conditions.

Comparison to Industry Standards

• The $300 million valuation is comparable to mid-sized biotech acquisitions seen in the protein degradation and targeted therapy space.
• The use of a tiered 18-month lock-up is a standard protective measure for significant all-stock mergers to maintain share price stability.
• The 19.99% ownership cap for conversion is a common provision to comply with Nasdaq listing rules regarding changes in control without prior shareholder approval.

Corporate Governance

Related Party Transactions

• Issuance of shares and options to Ying Luo and Ping Lan as part of the merger consideration for their previous holdings in Cullgen.

Stakeholder Impact

• Existing shareholders face dilution from the issuance of over 14 million new shares and potential preferred stock conversion.
• Cullgen shareholders become significant owners of Gyre Therapeutics with specific registration rights.
• Management's beneficial ownership is now clearly defined at 8.6% of the expanded company.

Next Steps

• Hold stockholder meeting on June 10, 2026.
• File resale registration statement with the SEC by June 18, 2026.
• Obtain shareholder approval for the Conversion Proposal to allow Series B Preferred Stock to convert to Common Stock.

Key Dates

Recommendation

While the acquisition adds significant value and assets, the substantial dilution and the pending shareholder vote on the preferred stock conversion suggest a cautious approach until the post-merger integration and capital structure are fully finalized.

Keywords

Gyre Therapeutics, Cullgen Inc, Merger, Acquisition, Schedule 13D, Series B Preferred Stock, Biotechnology, Ying Luo, Ping Lan